Industry News
Diffusion Optics Technology Spectacle Lenses Show Remarkable Myopia Control Performance
SightGlass Vision, a pioneer in myopia management solutions, has unveiled encouraging results from its extended four-year CYPRESS study, assessing the effectiveness of their revolutionary Diffusion Optics Technology™ (DOT 0.2) spectacle lenses in controlling myopia progression. These innovative lenses, employing thousands of light-scattering elements known as dots, aim to replicate natural contrast on the retina, offering a unique approach to slowing myopia progression in children.
The findings were officially presented at the 27th Congress of the Chinese Ophthalmological Society (CCOS), a biennial gathering attended by thousands of eye care clinicians, researchers, and educators from China and around the world.
The comprehensive study, titled "Control of Myopia using Diffusion Optics Technology Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 4 Year Results," led by Zhu X, McParland M, et al, reaffirmed the safety and efficacy of DOT 0.2 in children aged 6–10, as initially demonstrated in the study's inception. The second phase of the research, designed to collect an additional 12 months of data, re-enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial.
The full four-year results revealed statistically significant deceleration in axial length progression and cycloplegic spherical equivalent refraction (cSER). During the 36- to 48-month period, the mean change in axial length was 0.13 ± 0.02 mm for the test group (n=55) and 0.18 ± 0.02 mm for the control group (n=41; p=0.038). Similarly, the cSER mean change was -0.25 ± 0.04 D for the test group and -0.38 ± 0.05 D for the control group (p=0.043).
Andrew Sedgwick, CEO of SightGlass Vision, expressed his enthusiasm about the results, stating, "The CYPRESS four-year findings confirm the demonstrated efficacy, safety, and overall performance of Diffusion Optics Technology™ spectacle lenses. Eye care professionals worldwide are demanding this level of scientific rigor, allowing them to confidently recommend the lenses to children and their caregivers. SightGlass Vision is proud to advance the myopia control category with our latest research and technologies, and enthusiastic about growing opportunities for spectacles in a child's treatment regimen."
In a separate presentation at CCOS, experts explored the theoretical basis and practical application of DOT lenses. The discussion, titled "DOT Lenses Based on Contrast Reduction Theory and Real-World Case Sharing" (Wang D, Xie P, Huang J), delved into the impact of contrast on children's refractive development, the interaction between contrast signals and peripheral defocus signals, and the clinical performance of DOT lenses based on contrast reduction. After analyzing clinical observations of 117 Chinese children wearing DOT 0.2 lenses for one year, the investigators concluded that contrast management was effective and that the lenses were safe.
Over the past two years, SightGlass Vision's patent-protected technology, with clinically proven efficacy has made a successful commercial debut in several markets, including China, the Netherlands, and Israel, while undergoing preliminary market trials in other countries. The company operates as a joint venture between CooperCompanies and EssilorLuxottica.
